<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04558567</url>
  </required_header>
  <id_info>
    <org_study_id>P361-502</org_study_id>
    <nct_id>NCT04558567</nct_id>
  </id_info>
  <brief_title>Vogelxo(R) ABPM Study in Hypogandal Men</brief_title>
  <official_title>A Phase 4, Open-Label, Single-Arm Study to Evaluate the Effects of Vogelxo(R) on 24-hour Ambulatory Blood Pressure Monitoring in Hypogonadal Men Using Therapeutic Testosterone Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Upsher-Smith Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Upsher-Smith Laboratories</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 4 ABPM study in Hypogonadal Men&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single-arm, open-label, uncontrolled study consisting of a 4-week screening phase, 4-week&#xD;
      titration phase, and 16-week treatment phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 28, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the 24-hour ABPM average SBP</measure>
    <time_frame>20 weeks</time_frame>
    <description>Average SBP will be calculated from ABPM measurements taken twice each hour over the 24-hour period. An ABPM measurement session will be standardized and performed during on-site clinic visits at baseline (before treatment) and on the last day of treatment (week 20) to minimize subject variability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour average diastolic blood pressure (DBP)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour average heart rate (HR)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypogonadism, Male</condition>
  <arm_group>
    <arm_group_label>Open-Label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vogelxo</intervention_name>
    <description>50mg (1 tube, 5g gel) to 100mg (2 tubes, 10g gel)</description>
    <arm_group_label>Open-Label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult male whose age is between 18 and 80 years, inclusive, at the time of screening.&#xD;
&#xD;
          2. Considered by the investigator to be in good general health as determined by medical&#xD;
             history, clinical laboratory test results, vital sign measurements, 12-lead&#xD;
             electrocardiogram (ECG) results, and physical examination findings at screening.&#xD;
&#xD;
          3. Meets the study definition of clinical hypogonadism, as evidenced by serum&#xD;
             testosterone concentrations:&#xD;
&#xD;
               1. Two serum testosterone concentrations &lt; 300 ng/dL collected in the morning&#xD;
                  (between 0630 hours and 1000 hours local time) on at least 2 days separated by a&#xD;
                  minimum of 48 hours.&#xD;
&#xD;
               2. Presence of at least 1 sign or symptom that may be related to low testosterone&#xD;
                  values and is/are consistent with hypogonadism&#xD;
&#xD;
          4. Naïve to testosterone replacement, clomiphene, compounded or over-the-counter&#xD;
             androgenic steroid derivatives and dehydroepiandrosterone, including investigational&#xD;
             products that may affect the reproductive hormonal system within the past 2 months.&#xD;
&#xD;
          5. Willingness and the ability to apply topical testosterone gel as instructed by the&#xD;
             study staff and comply with the requirements of this study protocol.&#xD;
&#xD;
          6. Intact skin surfaces on the upper arms and shoulders where the topical testosterone&#xD;
             will be applied.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Two testosterone concentrations &lt; 100 ng/dL during screening.&#xD;
&#xD;
          2. Prolactin concentration &gt; 1 x upper limit of normal (ULN).&#xD;
&#xD;
          3. Current or recurrent ulcer, erosion, lichenification, inflammation psoriasis, eczema&#xD;
             or use of topical corticosteroids on the upper arms and shoulders. Tattoo application&#xD;
             or removal in the region of study drug application.&#xD;
&#xD;
          4. Known skin intolerance to alcohol or allergy to any of the ingredients of the study&#xD;
             drug.&#xD;
&#xD;
          5. History of treatment with growth hormone, anti-estrogen or estrogen treatment within&#xD;
             90 days prior to screening.&#xD;
&#xD;
          6. Currently taking glucocorticoids &gt; 7.5 mg prednisone equivalent per day (eg,&#xD;
             hydrocortisone 30 mg, methylprednisolone 6 mg, or dexamethasone 1.2 mg) for 1 week&#xD;
             before SV1 and through Day 1, and any use of opioids within 5 half-lives prior to Day&#xD;
             1.&#xD;
&#xD;
          7. Currently taking, unstable doses within 14 days prior to first administration of study&#xD;
             drug or anticipated to receive any antihypertensive medications, over-the-counter&#xD;
             medications, supplements or herbal medicines known to affect blood pressure during&#xD;
             study participation. These medications or supplements include diet pills (eg,&#xD;
             phenylpropanolamine, sibutramine), nasal decongestants (eg, phenylephrine&#xD;
             hydrochloride, pseudoephedrine, naphazoline hydrochloride), certain stimulants (eg,&#xD;
             amphetamine, methylphenidate dexmethylphenidate, dextroamphetamine), monoamine oxidase&#xD;
             inhibitors (MAO), atypical antipsychotics (eg, clozapine, olanzapine).&#xD;
&#xD;
          8. History of prostate (current or in the past) or breast cancer.&#xD;
&#xD;
          9. Severe lower urinary tract symptoms as indicated by an International Prostate Symptom&#xD;
             Score (I-PSS) &gt; 19.&#xD;
&#xD;
         10. Prostate-specific antigen (PSA) &gt; 3.0 ng/mL; men treated with 5-alpha reductase&#xD;
             inhibitors (eg, dutasteride, finasteride) are eligible for participation as long as&#xD;
             PSA levels are not &gt; 1.5 ng/mL.&#xD;
&#xD;
         11. Body mass index &gt; 50 kg/m2.&#xD;
&#xD;
         12. Sitting SBP &lt; 80 mm Hg and &gt; 150 mm Hg or sitting DBP &lt; 50 mm Hg and &gt; 100 mm Hg at&#xD;
             any point during screening.&#xD;
&#xD;
         13. HbA1c &gt; 11% at screening.&#xD;
&#xD;
         14. A current condition, therapy, laboratory abnormality, history of clinically&#xD;
             significant medical or psychiatric conditions or other circumstance or reasons which,&#xD;
             in the opinion of the investigator or the study staff, might pose a risk to the&#xD;
             subject, make participation not in the subject's best interest, confound the results&#xD;
             of the study (eg, if subject cannot comply with requirements of the study), make the&#xD;
             subject an unsuitable candidate to receive study drug, or interfere with the subject's&#xD;
             participation for the full duration of the study.&#xD;
&#xD;
         15. History, suspicion, or evidence of significant drug or alcohol abuse or illicit&#xD;
             steroid use within the previous 12 months prior to screening, as determined by the&#xD;
             investigator.&#xD;
&#xD;
         16. The subject is a smoker or has used nicotine or nicotine-containing products (eg,&#xD;
             snuff, nicotine patch, nicotine chewing gum, mock cigarettes, or inhalers) within 6&#xD;
             months before the first dose of study drug.&#xD;
&#xD;
         17. Clinical laboratory analysis shows any of the following abnormal results:&#xD;
&#xD;
               -  Hematocrit &gt; 50%&#xD;
&#xD;
               -  Alanine aminotransferase or aspartate aminotransferase &gt; 3 × ULN&#xD;
&#xD;
         18. Severe or end-stage chronic kidney disease documented by eGFR &lt; 30 mL/min.&#xD;
&#xD;
         19. Subject works night shifts.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>1-888-650-3789</phone>
    <email>uslinfo@upsher-smith.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #2</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trial Site #1</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upsher-Smith Clinical Trials Site #3</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

